RecruitingNCT06315868

Breast Cancer Subtype Characterization Through Patient's Derived Organoids.

Breast Cancer Subtype Characterization Through Patient's Derived Organoids". (BCinsightPDO)

Sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Enrollment

306 participants

Start Date

Jun 15, 2023

Study Type

OBSERVATIONAL

Conditions

Breast Cancer Organoids

Summary

Development of tools to predict patients chemo-sensitivity and identification of corresponding biomarkers is an urgent challenge for BC patients lacking targeted therapies, such as TNBC, or for patients experiencing relapse after adjuvant chemotherapy or targeted therapies. The refinement of 3D-cultivation techniques, experienced in the last decade, has allowed cultivation of patients-derived cancer cells in organotypic structures, named patient-derived organoids (PDO), which preserve histologic, genomic and transcriptomic features of primary tumors. PDO allow propagation, pharmacological treatment and genetic manipulation of patients-derived cancer cells in a close to physiology setting, thus representing a promising tool in the development of personalized therapies

Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This study is creating mini-tumors in the lab called organoids — tiny 3D models grown from a patient's own breast cancer tissue — to better understand the different subtypes of breast cancer. These models help researchers test treatments and study cancer behavior more accurately than traditional methods. **You may be eligible if...** - You are a woman between 18 and 70 years old - You have been newly diagnosed with primary breast cancer - Your tumor is at least 1.5 cm in diameter - You are eligible for surgical removal of your tumor according to standard guidelines **You may NOT be eligible if...** - You were diagnosed with breast cancer during pregnancy - You have already received or are currently receiving neoadjuvant chemotherapy (chemo given before surgery) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(1)

IRCCS Fondazione Policlinico A. Gemelli

Roma, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06315868

Related Trials

Genomic Services Research Program

NCT025959571 location

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

NCT052833304 locations

A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast)

NCT070671381 location

Social and Environmental Determinants of Breast Cancer Survivorship: the Black Breast Cancer Survivor's Intervention (BBCSI)

NCT068852031 location

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

NCT06103864316 locations